Corporate | 29 May 2009 17:41
Eckert & Ziegler Strahlen- und Medizintechnik AG / Legal Matter
Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------
Berlin, 29.5.2009 - Further to its press release of 28 April 2009, and on
the request of the Belgian securities regulator (CBFA), Eckert & Ziegler
(ISIN DE0005659700) publicly confirms that it will, next week, lodge an
appeal with the Court of Appeal of Brussels against the decision of the
CBFA ordering it to launch a mandatory public takeover bid on International
Brachytherapy at EUR 3.47 per share.
Eckert & Ziegler will request from the Court a preliminary decision
suspending the execution of the decision of the CBFA. In the event that the
Court would rule against Eckert & Ziegler in such preliminary decision, the
acceptance period of the mandatory public takeover bid would then have to
start within 40 working days after such Court decision.
Eckert & Ziegler maintains that it has not violated any rules and is
determined to vigorously defend the position that no public takeover bid is
required under applicable rules.
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, D-13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, Fax -112
E-Mail: karolin.riehle@ezag.de, www.ezag.de
29.05.2009 Financial News transmitted by DGAP
----------------------------------------------------------------------
Language: English
Issuer: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Deutschland
Phone: 49 30 941084138
Fax: 49 30 941084112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700, ISIN DE0005659700
WKN: 565970, ISIN DE000A0L1L69
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, München, Hamburg, Düsseldorf
End of News DGAP News-Service
---------------------------------------------------------------------------